• 1.四川大學華西醫(yī)院胃腸外科(成都610041);;
  • 2.四川大學華西第二醫(yī)院婦產科(成都610041);;
  • 3.四川大學華西醫(yī)院肛腸外科(成都610041);

目的 探討腫瘤壞死因子相關凋亡誘導配體(TRAIL)及其受體(DR4、DcR1)在正常直腸和直腸癌組織中的表達。
方法 在31例直腸癌和20例正常直腸組織中，用免疫組化法檢測TRAIL、DR4和DcR1的蛋白表達。
結果 直腸癌組織中TRAIL、DR4和DcR1蛋白的表達陽性率（32.26%、29.03%、0）均低于正常直腸組織（55.00%、70.00%、65.00%），差異均有統(tǒng)計學意義(P=0.015、P=0.000、P=0.000)，TRAIL及其受體的表達與直腸癌臨床病理特征間無關（P gt;0.05）。
結論 直腸癌組織中TRAIL、DR4和DcR1的表達低于正常直腸組織，TRAIL及其受體相互作用所誘導的凋亡效應在直腸癌中有所減弱。

引用本文： 胡建昆,楊昆,李春梅,周總光,張波,于永揚,陳心足,李立,陳志新,陳佳平. TRAIL及其受體在直腸癌組織中的表達. 中國普外基礎與臨床雜志, 2009, 16(2): 137-140. doi: 復制

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008[Ｊ]. CA Cancer J Clin, 2008; 58(2)： 71.
2. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand[Ｊ]. J Clin Invest, 1999; 104(2)： 155.
3. Fernandes BJ, Yao XY, Hao Y, et al. DNA content and estrogen receptors in primary carcinoma of the breast[Ｊ]. Can J Surg, 1991; 34(4)： 349.
4. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis[Ｊ]. Immunity, 1995; 3(6)： 673.
5. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors[Ｊ]. Science, 1997; 277(5327)： 818.
6. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL[Ｊ]. J Biol Chem, 1998; 273(23)： 14363.
7. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms[Ｊ]. Curr Opin Immunol, 1998; 10(5)： 559.
8. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo[Ｊ]. Nat Med, 1999; 5(2)： 157.
9. Sheikh MS, Huang Y, Fernandez-Salas EA, et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract[Ｊ]. Oncogene, 1999; 18(28)： 4153.
10. 公偉，　劉軍， 梁飛， 等.TRAIL受體在胰腺癌中的表達 [Ｊ]. 中國普外基礎與臨床雜志,2006;13(5)： 521.
11. Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5[Ｊ]. Immunity, 2000; 12(6)： 611.
12. Xu SQ, El-Deiry WS. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4[Ｊ]. Biochem Biophys Res Commun, 2000; 269(1)： 179.
13. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL[Ｊ]. Science, 1997; 277(5327)： 815.
14. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors[Ｊ]. Cell Res, 2004; 14(5)： 359.
15. 陳心足， 姜坤， 胡建昆. TRAIL信號通路在胃癌的研究現狀 [Ｊ]. 中國普外基礎與臨床雜志,2007;14(3)： 371.
16. Liu P, Mao H, Hou P. Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo[Ｊ]. Int J Gynecol Cancer, 2006; 16(2)： 538.
17. 公偉， 李占元， 曾慶東， 等.腫瘤壞死因子相關凋亡誘導配體聯(lián)合化療藥物殺傷胰腺癌細胞的研究 [Ｊ].中華肝膽外科雜志,2006;12(2)： 111.
18. Itashiki Y，Harada K， Ferdous T,et al.Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice[Ｊ]. Anticancer Res, 2007; 27(4B)： 2365.
19. Xu J, Zhou JY, Tainsky MA, et al. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2’-deoxycytidine sensitizes human breast cancer cells to adriamycin[Ｊ]. Cancer Res, 2007; 67(3)： 1203.
20. Arts HJ, de Jong S, Hollema H, et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma[Ｊ]. Gynecol Oncol, 2004; 92(3)： 794.
21. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo[Ｊ]. Prostate, 2005; 62(2)： 165.
22. Baritaki S, Huerta-Yepez S, Sakai T, et al. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1[Ｊ]. Mol Cancer Ther, 2007; 6(4)： 1387.
  1. 1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008[Ｊ]. CA Cancer J Clin, 2008; 58(2)： 71.
  2. 2. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand[Ｊ]. J Clin Invest, 1999; 104(2)： 155.
  3. 3. Fernandes BJ, Yao XY, Hao Y, et al. DNA content and estrogen receptors in primary carcinoma of the breast[Ｊ]. Can J Surg, 1991; 34(4)： 349.
  4. 4. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis[Ｊ]. Immunity, 1995; 3(6)： 673.
  5. 5. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors[Ｊ]. Science, 1997; 277(5327)： 818.
  6. 6. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL[Ｊ]. J Biol Chem, 1998; 273(23)： 14363.
  7. 7. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms[Ｊ]. Curr Opin Immunol, 1998; 10(5)： 559.
  8. 8. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo[Ｊ]. Nat Med, 1999; 5(2)： 157.
  9. 9. Sheikh MS, Huang Y, Fernandez-Salas EA, et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract[Ｊ]. Oncogene, 1999; 18(28)： 4153.
  10. 10. 公偉，　劉軍， 梁飛， 等.TRAIL受體在胰腺癌中的表達 [Ｊ]. 中國普外基礎與臨床雜志,2006;13(5)： 521.
  11. 11. Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5[Ｊ]. Immunity, 2000; 12(6)： 611.
  12. 12. Xu SQ, El-Deiry WS. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4[Ｊ]. Biochem Biophys Res Commun, 2000; 269(1)： 179.
  13. 13. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL[Ｊ]. Science, 1997; 277(5327)： 815.
  14. 14. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors[Ｊ]. Cell Res, 2004; 14(5)： 359.
  15. 15. 陳心足， 姜坤， 胡建昆. TRAIL信號通路在胃癌的研究現狀 [Ｊ]. 中國普外基礎與臨床雜志,2007;14(3)： 371.
  16. 16. Liu P, Mao H, Hou P. Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo[Ｊ]. Int J Gynecol Cancer, 2006; 16(2)： 538.
  17. 17. 公偉， 李占元， 曾慶東， 等.腫瘤壞死因子相關凋亡誘導配體聯(lián)合化療藥物殺傷胰腺癌細胞的研究 [Ｊ].中華肝膽外科雜志,2006;12(2)： 111.
  18. 18. Itashiki Y，Harada K， Ferdous T,et al.Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice[Ｊ]. Anticancer Res, 2007; 27(4B)： 2365.
  19. 19. Xu J, Zhou JY, Tainsky MA, et al. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2’-deoxycytidine sensitizes human breast cancer cells to adriamycin[Ｊ]. Cancer Res, 2007; 67(3)： 1203.
  20. 20. Arts HJ, de Jong S, Hollema H, et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma[Ｊ]. Gynecol Oncol, 2004; 92(3)： 794.
  21. 21. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo[Ｊ]. Prostate, 2005; 62(2)： 165.
  22. 22. Baritaki S, Huerta-Yepez S, Sakai T, et al. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1[Ｊ]. Mol Cancer Ther, 2007; 6(4)： 1387.